Aqua Sphere Welcomes Three-Time World Champion Triathlete Mirinda Carfrae to the Team
25.8.2020 12:00:00 EEST | Business Wire | Press release
Aqua Sphere, the premier swimming and triathlon equipment brand, today announced World Champion triathlete Mirinda “Rinny” Carfrae is joining the team as a global brand ambassador. As part of the Aqua Sphere team of athletes, Carfrae will train and compete utilizing the industry-leading Aqua Sphere range of products from training equipment to performance swimsuits and goggles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005255/en/
Mirinda "Rinny" Carfrae joins premier swimming and triathlon equipment brand Aqua Sphere as a global brand ambassador. (Photo: Business Wire)
Carfrae, a three-time Ironman World Champion, will help grow the brand globally alongside her husband and fellow World Champion triathlete, Timothy O’Donnell. Carfrae and O’Donnell are part of Aqua Sphere’s growing roster of elite athletes that also includes World Champion Terenzo Bozzone, among others.
“I’m thrilled to be joining the Aqua Sphere team alongside my husband, Tim. I appreciate the long-term brand vision and I’m confident that Tim and I can make an immediate impact, especially as we embark on product designs heading into 2021,” said Carfrae. “Aqua Sphere has a significant global reach and their wide range of categories fit all our training and racing needs. The goggles fit great and have perfect clarity and I can’t wait to race in the gear once we start competitions again. Everyone we have worked with at Aqua Sphere shares an amazing passion for the brand and has welcomed us like family. And yes, the kid’s goggles are also Izzy approved.”
As a leader in the development of new and innovative swim products for athletes of all ages and abilities, Aqua Sphere has tapped Carfrae to endorse its entire product portfolio, including eye protection, swimwear, triathlon wetsuits and speedsuits, and swim fitness and training accessories. She will also contribute her unique perspective and insight to future product innovations.
“Rinny is a world class athlete who is dedicated to her sport and her family, and we are fortunate to have her join our team at Aqua Sphere,” said Andrew Gritzbaugh, General Manager of Aqua Lung, the parent company of Aqua Sphere. “As one of the world’s most decorated female triathletes, her experience, insights and talent are welcomed assets to the Aqua Sphere brand as we continue to solidify our category leadership position in the triathlon space.”
Originally from Australia, and now residing in Boulder, Colo., Carfrae is one of the world’s most successful triathletes. She has won three Ironman World Championships in 2010, 2013, and 2014 and her run course record from 2014 still stands today (2:50:26). With over 50 wins at major events throughout the world and seven podium performances at Kona in the span of a decade, Carfrae is recognized as one the of the greatest triathletes of all time.
Carfrae is currently gearing up to compete at Ironman World Championships – Kona in 2021.
About AQUA SPHERE
Established in Genoa, Italy, in 1998, Aqua Sphere is the premier swimming and triathlon equipment brand. With the launch of its cutting-edge Seal Mask—the world’s first swim mask, the company set the industry standard and today continues to innovate with a complete range of premium products, including eye protection, swimwear, triathlon wetsuits, speedsuits, swim fitness and training accessories. The designs have gained the respect and loyal following of many celebrities and notable athletes, including the world’s most decorated Olympian Michael Phelps, with whom Aqua Sphere has launched Phelps, a global brand of performance swimwear. Alongside its parent company Aqua Lung and supported by an international distribution network, Aqua Sphere has grown into a worldwide enterprise representing unparalleled design, development and manufacturing expertise, with a global footprint in more than 60 countries. For more information, visit: www.AquaSphereSwim.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005255/en/
Contact information
Lindsay Goodson
lgoodson@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom